Medtronic (NYSE: MDT)+
announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering.

Cardiawave announced that it received CE mark approval for Valvosoft, its non-invasive therapeutic alternative for treating aortic stenosis (AS).